The case for & against
Bull & Bear analysis
Bearish
Five Prime Therapeutics (FPRX) was a clinical-stage biotechnology company focused on developing protein therapeutics, with a significant emphasis on immuno-oncology and targeted cancer therapies. Acquired by Amgen in April 2021 for $1.9 billion, the company ceased to operate independently and thus has no recent news or stock performance reports as a standalone entity. The acquisition allows Amgen to integrate Five Prime's promising pipeline, which included candidates such as Bemarituzumab and Cabiralizumab, enhancing its position in the oncology market.
Bull says
- ↑Amgen’s $1.9B acquisition secures Bemarituzumab and Cabiralizumab
- ↑Bemarituzumab Phase II data shows robust immuno-oncology efficacy
- ↑Amgen’s $6B annual R&D budget accelerates candidate development
- ↑Global commercial reach boosts launch prospects for Five Prime assets
- ↑Rising demand for targeted cancer therapies supports valuation
- ↑Amgen’s strong balance sheet guarantees pipeline funding
Bear says
- ↓FPRX ceased independent operations after April 2021 acquisition
- ↓No standalone stock means zero direct upside for FPRX investors
- ↓Integration risk as Five Prime assets may lose strategic focus
- ↓Clinical setbacks in Bemarituzumab could dent Amgen’s oncology results
- ↓$1.9B price tag risks overvaluation if trials fail
- ↓Biotech volatility and regulatory delays may push commercialization out